Drug intelligence / Profile preview

AOC 1086

Development stage: Preclinical
Lead developer: Atrium Therapeutics
Modality: Antibody Conjugates → Antibody-Based Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

AOC 1086 is an early-stage Antibody Oligonucleotide Conjugate (AOC) developed by Avidity Biosciences, now held by SpinCo (Bryce Therapeutics, Inc.) following Novartis's acquisition of Avidity. This drug is focused on treating rare genetic cardiomyopathies and leverages Avidity's proprietary AOC platform for targeted RNA delivery. It is currently part of collaboration agreements with Bristol Myers Squibb and Eli Lilly.

Targets

PLN (Phospholamban)

Beyond the preview

Go deeper on AOC 1086.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AOC 1086.